CARsgen Advances Allogeneic CAR T Programs as EHA Accepts New Data for 2026

CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has shared an update.

CARsgen Therapeutics said investigator-initiated trial data for its allogeneic CAR T-cell candidates CT0596 and CT1190B have been accepted for poster presentation at the 2026 European Hematology Association congress, underscoring progress in its off-the-shelf cell therapy pipeline. CT0596, which targets BCMA, is being studied in refractory or relapsed multiple myeloma and plasma cell leukemia and has shown favorable tolerability and encouraging efficacy signals, with Phase Ib trials in R/R multiple myeloma and primary plasma cell leukemia planned for 2026.

CT1190B, an allogeneic CAR T-cell therapy targeting CD19/CD20, is in investigator-initiated trials for refractory or relapsed B-cell non-Hodgkin lymphoma as well as difficult-to-treat autoimmune conditions such as systemic lupus erythematosus and systemic sclerosis, with a Phase Ib study in R/R B-NHL also slated for 2026. The acceptance at EHA and the planned Phase Ib programs highlight CARsgen’s push to advance its THANK-u Plus platform into broader indications, potentially strengthening its competitive position in the emerging allogeneic CAR T space if future trials confirm safety and efficacy.

The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.

More about CARsgen Therapeutics Holdings Ltd.

CARsgen Therapeutics Holdings Ltd. is a biopharmaceutical company specializing in innovative CAR T-cell therapies targeting hematologic malignancies, solid tumors, and autoimmune diseases. The group has end-to-end capabilities from target discovery and preclinical research to clinical development and commercial-scale production, and is focused on improving safety, efficacy, and cost profiles of cell therapies for global markets.

Average Trading Volume: 5,105,904

Technical Sentiment Signal: Buy

Current Market Cap: HK$14.28B

Learn more about 2171 stock on TipRanks’ Stock Analysis page.